Vulnerability Details : CVE-2022-25152
The ITarian platform (SAAS / on-premise) offers the possibility to run code on agents via a function called procedures. It is possible to require a mandatory approval process. Due to a vulnerability in the approval process, present in any version prior to 6.35.37347.20040, a malicious actor (with a valid session token) can create a procedure, bypass approval, and execute the procedure. This results in the ability for any user with a valid session token to perform arbitrary code execution and full system take-over on all agents.
Published
2022-06-09 17:15:09
Updated
2022-06-16 14:56:22
Products affected by CVE-2022-25152
- cpe:2.3:a:itarian:saas_service_desk:*:*:*:*:*:*:*:*
- cpe:2.3:a:itarian:on-premise:*:*:*:*:*:*:*:*
Exploit prediction scoring system (EPSS) score for CVE-2022-25152
0.14%
Probability of exploitation activity in the next 30 days
EPSS Score History
~ 31 %
Percentile, the proportion of vulnerabilities that are scored at or less
CVSS scores for CVE-2022-25152
Base Score | Base Severity | CVSS Vector | Exploitability Score | Impact Score | Score Source | First Seen |
---|---|---|---|---|---|---|
9.0
|
HIGH | AV:N/AC:L/Au:S/C:C/I:C/A:C |
8.0
|
10.0
|
NIST | |
9.9
|
CRITICAL | CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H |
3.1
|
6.0
|
Dutch Institute for Vulnerability Disclosure | |
8.8
|
HIGH | CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H |
2.8
|
5.9
|
NIST |
CWE ids for CVE-2022-25152
-
The product does not implement or incorrectly implements one or more security-relevant checks as specified by the design of a standardized algorithm, protocol, or technique.Assigned by: csirt@divd.nl (Secondary)
References for CVE-2022-25152
-
https://csirt.divd.nl/CVE-2022-25152
ITarian - Any user with a valid session token can create and execute agent procedures and bypass mandatory approvals | DIVD CSIRTThird Party Advisory
-
https://csirt.divd.nl/DIVD-2021-00037
DIVD-2021-00037 - Critical vulnerabilities in ITarian MSP platform and on-premise solution | DIVD CSIRTThird Party Advisory
Jump to